
Chinese biopharmaceutical company founded in 2015 and registered in the Banan district of Chongqing, listed on the Shanghai Stock Exchange STAR Market under code 688443. Specialises in the research, development and industrialisation of novel monoclonal antibody drugs across three therapeutic areas - autoimmune disease, infectious disease and oncology - with research subsidiaries and offices in Beijing, Shanghai and Hefei and around four hundred staff. Its pipeline covers sixteen products, of which two indications of its anti-IL-17A antibody have been approved and added to the national reimbursement list, while marketing applications for its rabies bispecific antibody and its anti-IL-4R antibody have been accepted.
Bewertung hinterlassen